Tag: VEITH 2023
TRANSCEND 36-month data “continue to demonstrate safe and effective performance” of...
Peter Schneider (University of California San Francisco, San Francisco, USA) recently presented 36-month data from Surmodics' TRANSCEND clinical trial at the VEITHsymposium 2023 (14–18...
Twelve-month first-in-human data from Xeltis’ aXess haemodialysis vascular conduit trial presented...
Xeltis has announced "highly encouraging" 12-month results from its first-in-human (FIH) aXess vascular conduit trial. The data were presented by Frans Moll (University Medical...
Randomised trial set to elucidate value of image fusion technology for...
An ongoing UK National Institute for Health and Care Research (NIHR)-funded randomised controlled trial seeks to illuminate the value of an image fusion guidance...
Two-year SWING data “continue to show promise” for sirolimus DCB in...
Two-year data from the SWING trial, a first-in-human study of the safety and performance of the Sundance sirolimus drug-coated balloon (DCB; Surmodics), have been...
Getinge announces US commercial availability of iCast covered stent system for...
Getinge has announced commercial availability of the iCast covered stent system in the USA for the treatment of iliac arterial occlusive disease. In March...
